Skip to Content
William J Burlingham, PhD

Contact Dr. Burlingham


(608) 263-0388

600 Highland Ave
MC 7375
Madison, WI 53792-3284

William J Burlingham, PhD

Division of Transplantation


  • PhD, Biology, Syracuse University, Syracuse, NY, 1979
  • Postdoctoral Research Fellowship, National Cancer Institute, Mayo Clinic and Mayo Medical School, Rochester, MN, 1980-1983

Professional Activities

Dr. Burlingham serves on the editorial board of Transplantation. He is also the chairman of the University of Wisconsin Spring Immunology Seminar Series.

Research Interests

Dr. Burlingham has developed a highly respected transplant basic research program that focuses on acquired immunologic tolerance. His laboratory hopes to gain insight into graft acceptance by studying transplant recipients who have survived after stopping immunosuppressive drugs.

Specifically, his research focuses on the natural exchange of soluble antigens and low numbers of white blood cells that occurs between mother and child during pregnancy and nursing. The lab’s working hypothesis is that this exchange, which leads to persistence of bone marrow-derived maternal blood cells within the offspring (“microchimerism”) may induce a “natural” form of tolerance. This tolerance, if harnessed, may allow for drug-free acceptance of transplanted grafts. Such natural tolerance has recently been shown to be the result, not of having microchimerism per se, but having a specific type of rare maternal cells capable of producing exosomes— tiny virus-like vesicles composed of lipid, protein, and nucleic acids. The goal is now to investigate how these intercellular messengers modify the host antigen presenting cells, and T cells during tolerance, with a view toward therapeutic applications.

The other major focus of Dr. Burlingham’s lab is the phenomenon of autoimmunity that develops after lung transplantation. A novel type of T Cells, called Th-17, react to collagen type V and cause inflammation and over-production of collagens causing airway blockage and graft loss. His lab is working on ways to inhibit this process by new forms of immune suppressive drugs and by increasing T regulatory cells that normally prevent autoimmune disease.

View Dr. Burlingham’s Google Scholar Citations Profile.

Dr. Burlingham's Lab

Active Clinical Trials

Recent Publications
  • Functional characterization of human pluripotent stem cell-derived arterial endothelial cells.
    Zhang J, Chu LF, Hou Z, Schwartz MP, Hacker T, Vickerman V, Swanson S, Leng N, Nguyen BK, Elwell A, Bolin J, Brown ME, Stewart R, Burlingham WJ, Murphy WL, Thomson JA
    Proc. Natl. Acad. Sci. U.S.A. 2017 Jul 25; 114(30):E6072-E6078.
    [PubMed ID: 28696312, PMC ID: 5544294]
    More Information
  • Donor-derived exosomes: the trick behind the semidirect pathway of allorecognition.
    Morelli AE, Bracamonte-Baran W, Burlingham WJ
    Curr Opin Organ Transplant 2017 Feb; 22(1):46-54.
    [PubMed ID: 27898464, PMC ID: 5407007]
    More Information
  • Modification of host dendritic cells by microchimerism-derived extracellular vesicles generates split tolerance.
    Bracamonte-Baran W, Florentin J, Zhou Y, Jankowska-Gan E, Haynes WJ, Zhong W, Brennan TV, Dutta P, Claas FH, van Rood JJ, Burlingham WJ
    Proc. Natl. Acad. Sci. U.S.A. 2017 Jan 31; 114(5):1099-1104.
    [PubMed ID: 28096390, PMC ID: 5293109]
    More Information
  • Th17 Responses to Collagen Type V, kα1-Tubulin, and Vimentin Are Present Early in Human Development and Persist Throughout Life.
    Sullivan JA, Jankowska-Gan E, Hegde S, Pestrak MA, Agashe VV, Park AC, Brown ME, Kernien JF, Wilkes DS, Kaufman DB, Greenspan DS, Burlingham WJ
    Am. J. Transplant. 2017 Apr; 17(4):944-956.
    [PubMed ID: 27801552, PMC ID: 5626015]
    More Information
  • "Cross-Dressing" Becomes Fashionable Among Transplant Recipients.
    Burlingham WJ
    Am. J. Transplant. 2017 Jan; 17(1):5-6.
    [PubMed ID: 27589607]
    More Information Copyright © 2017 The Board of Regents of the University of Wisconsin System